DYRK1A and Down syndrome: EGCG was initially identified as a candidate therapeutic treatment for Down syndrome (DS) phenotypes based largely on the in vitro demonstration that EGCG inhibits Dual-specificity tyrosine-phosphorylation regulated kinase 1A (DYRK1A) activity8,9.